LAUSR

The advent, efficacy, followed by the undiscerning and unrestricted consumption of antibiotics resulted in undue evolution in microbes in the form of multidrug resistance eventually resulting in the cultivation of new challenges to develop the new-generation antimicrobial therapy. A critical need for the development of novel, broad-spectrum therapeutics has thus arrived. The Silver nanoparticles (AgNPs) over the last few years have gained immense reputation as the next-generation antibiotics owing to their broad-spectrum activity against the disease-causing microbes which has been also extended against the highly evolved MDR strains. Also known to support the synergistic effect in combination with various commercially used antibiotics, the potential of AgNPs could be extensively exploited to gradually replace the old-generation drugs that certainly have lost their tooth against the resistant microbes.